[144] Bicara Therapeutics Inc. SEC Filing

Rhea-AI Filing Summary

BCAX filing reports a proposed sale of 6,905 shares of Common Stock on 03/19/2026 following an exercise of stock options for cash. The notice lists multiple prior dispositions by Claire Mazumdar in the past three months, including 3/9/2026: 36,766 shares and 3/18/2026: 6,499 shares.

Insights

Corporate Governance Analyst

Routine Form 144 notice: option exercise then planned resale by reporting person.

The filing shows a proposed sale of 6,905 shares on 03/19/2026 following an exercise of stock options for cash. The seller is identified as Claire Mazumdar and prior open-market dispositions are listed for March.

These notices are procedural disclosures of intended resales; cash‑flow treatment and whether sales were under a trading plan are not stated in the excerpt. Subsequent trade reports will show actual market transactions.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	UBS Financial Services, Inc. 11 Madison Ave 4th Floor New York NY 10010	6905	129704.90	54781950	03/19/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	03/19/2026	Exercise of stock options	Issuer			6905	03/19/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Claire Mazumdar 116 HUNTINGTON AVENUE SUITE 703 Boston MA 02116	Common	03/04/2026	2631	49288.63
Claire Mazumdar 116 HUNTINGTON AVENUE SUITE 703 Boston MA 02116	Common	03/05/2026	1786	33464.10
Claire Mazumdar 116 HUNTINGTON AVENUE SUITE 703 Boston MA 02116	Common	03/06/2026	3817	71571.80
Claire Mazumdar 116 HUNTINGTON AVENUE SUITE 703 Boston MA 02116	Common	03/09/2026	36766	704657.16
Claire Mazumdar 116 HUNTINGTON AVENUE SUITE 703 Boston MA 02116	Common	03/18/2026	6499	122414.51

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)